Stock Price Action: Learn Why Empery Asset Management Just Purchased Delcath Systems, Inc Stake?

Stock Price Action: Learn Why Empery Asset Management Just Purchased Delcath Systems, Inc Stake?

The New Empery Asset Management Holding in Delcath Systems, Inc

Empery Asset Management filed with the SEC SC 13G form for Delcath Systems, Inc. The form can be accessed here: 000090266416008303. As reported in Empery Asset Management’s form, the filler as of late owns 5.14% or 100,000 shares of the Health Care–company.

Delcath Systems, Inc stake is a new one for the and it was filed because of activity on September 30, 2016. We feel this shows Empery Asset Management’s positive view for the stock.

Delcath Systems, Inc Institutional Sentiment

Latest Security and Exchange filings show 22 investors own Delcath Systems, Inc. The institutional ownership in Q3 2015 is low, at 330.82% of the outstanding shares. This is increased by 4880230 the total institutional shares. 6450954 were the shares owned by these institutional investors. In total 5 funds opened new Delcath Systems, Inc stakes, 4 increased stakes. There were 6 that closed positions and 4 reduced them.

Brookstone Capital Management is an institutional investor bullish on Delcath Systems, Inc, owning 240 shares as of Q3 2015 for less than 0.01% of its portfolio. Vanguard Group Inc owns 4485838 shares or 0.01% of its portfolio. NY Allsquare Wealth Management Llc have less than 0.01% of their stock portfolio for 125 shares. Further, Private Advisor Group Llc reported stake worth 0.01% of its US stock portfolio. The NY Cowen Group Inc owns 486300 shares. Delcath Systems, Inc is 0.01% of the manager’s US portfolio.

Business Profile

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Insitutional Activity: The institutional sentiment decreased to 1.13 in Q2 2016. Its down 0.30, from 1.43 in 2016Q1. The ratio turned negative, as 7 funds sold all Delcath Systems, Inc. shares owned while 1 reduced positions. 2 funds bought stakes while 7 increased positions. They now own 1.85 million shares or 18.13% less from 2.26 million shares in 2016Q1.

Barclays Public Ltd Company owns 15 shares or 0% of their US portfolio. Group One Trading Lp reported 5,123 shares or 0% of all its holdings. Natl Bank Of America De holds 4,604 shares or 0% of its portfolio. Blackrock Institutional Na has 531,871 shares for 0% of their US portfolio. Blackrock Fund last reported 0% of its portfolio in the stock. The Pennsylvania-based Susquehanna Ltd Liability Partnership has invested 0% in Delcath Systems, Inc. (NASDAQ:DCTH). Deutsche Bancorp Ag last reported 0% of its portfolio in the stock. Vanguard Grp Inc reported 77,988 shares or 0% of all its holdings. Creative Planning reported 307 shares or 0% of all its holdings. Goldman Sachs Gp accumulated 0% or 15,211 shares. Ladenburg Thalmann Fincl Services Inc has 0% invested in the company for 1,456 shares. The Illinois-based Citadel Advsrs Ltd Liability Corp has invested 0% in Delcath Systems, Inc. (NASDAQ:DCTH). Private Advisor Gru Ltd Llc accumulated 206,670 shares or 0% of the stock. Geode Cap Mngmt Ltd Liability Company has 0% invested in the company for 39,792 shares. Royal National Bank Of Canada, a Ontario – Canada-based fund reported 2,563 shares.

Analysts await Delcath Systems, Inc. (NASDAQ:DCTH) to report earnings on November, 8.

The stock decreased 0.37% or $0.01 on October 6, hitting $2.72. About 28,633 shares traded hands. Delcath Systems, Inc. (NASDAQ:DCTH) has declined 41.16% since March 3, 2016 and is downtrending. It has underperformed by 49.51% the S&P500.

Delcath Systems, Inc. is a late-stage clinical development firm with early commercial activity in Europe focused on cancers of the liver. The company has a market cap of $4.43 million. The Firm is a specialty pharmaceutical and medical device firm developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System . It currently has negative earnings. The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT).

More notable recent Delcath Systems, Inc. (NASDAQ:DCTH) news were published by: Marketwatch.com which released: “Delcath Systems Inc.” on December 22, 2009, also Prnewswire.com with their article: “Delcath Sponsors Ocular Melanoma Foundation Patient Retreat” published on September 19, 2016, Prnewswire.com published: “Delcath To Present At The 2016 Aegis Growth Conference” on September 12, 2016. More interesting news about Delcath Systems, Inc. (NASDAQ:DCTH) were released by: Prnewswire.com and their article: “European Data Supporting Survival Benefit With Delcath’s CHEMOSAT System …” published on July 06, 2016 as well as Seekingalpha.com‘s news article titled: “Delcath prices stock offering at $3; shares off 21%” with publication date: September 30, 2016.

According to Zacks Investment Research, “Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.”

DCTH Company Profile

Delcath Systems, Inc., incorporated on August 5, 1988, is a late-stage clinical development firm with early commercial activity in Europe focused on cancers of the liver. The Firm is a specialty pharmaceutical and medical device firm developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment